CytoMed Therapeutics Net Income vs. Total Debt
| GDTC Stock | 1.02 0.07 7.37% |
Net Loss | First Reported 2020-03-31 | Previous Quarter -835 K | Current Value -882.3 K | Quarterly Volatility 400.1 K |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.84 | 0.91 |
|
|
For CytoMed Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CytoMed Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CytoMed Therapeutics Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CytoMed Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CytoMed Therapeutics Limited over time as well as its relative position and ranking within its peers.
Check out Risk vs Return Analysis. Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
CytoMed Therapeutics Total Debt vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CytoMed Therapeutics's current stock value. Our valuation model uses many indicators to compare CytoMed Therapeutics value to that of its competitors to determine the firm's financial worth. CytoMed Therapeutics Limited is one of the top stocks in net income category among its peers. It is rated # 5 in total debt category among its peers . At present, CytoMed Therapeutics' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CytoMed Therapeutics' earnings, one of the primary drivers of an investment's value.CytoMed Total Debt vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
CytoMed Therapeutics |
| = | (1.84 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
CytoMed Therapeutics |
| = | 339.2 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CytoMed Total Debt vs Competition
CytoMed Therapeutics Limited is rated # 5 in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 36.42 Million. CytoMed Therapeutics maintains roughly 339,200 in total debt contributing less than 1% to equities under Health Care industry.
CytoMed Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CytoMed Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CytoMed Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of CytoMed Therapeutics' change in net profit over the period of time. It can combine multiple indicators of CytoMed Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 13.3 K | 12.7 K | |
| Operating Income | -2.4 M | -2.5 M | |
| Income Before Tax | -1.7 M | -1.8 M | |
| Total Other Income Expense Net | 850 K | 892.5 K | |
| Net Loss | -2.8 M | -3 M | |
| Net Loss | -1.7 M | -1.7 M | |
| Net Interest Income | 342 K | 359.1 K | |
| Interest Income | 365.3 K | 383.6 K | |
| Net Loss | -2.3 M | -2.4 M | |
| Income Tax Expense | 437.55 | 415.68 | |
| Change To Netincome | 1.4 M | 1.5 M | |
| Net Loss | (0.19) | (0.20) | |
| Income Quality | 0.97 | 0.58 | |
| Net Income Per E B T | 1.15 | 1.12 |
CytoMed Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CytoMed Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CytoMed Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CytoMed Therapeutics' important profitability drivers and their relationship over time.
CytoMed Therapeutics Earnings per Share Projection vs Actual
Use CytoMed Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytoMed Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytoMed Therapeutics will appreciate offsetting losses from the drop in the long position's value.CytoMed Therapeutics Pair Trading
CytoMed Therapeutics Limited Pair Trading Analysis
The ability to find closely correlated positions to CytoMed Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytoMed Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytoMed Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytoMed Therapeutics Limited to buy it.
The correlation of CytoMed Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytoMed Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytoMed Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytoMed Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your CytoMed Therapeutics position
In addition to having CytoMed Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
To fully project CytoMed Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CytoMed Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CytoMed Therapeutics' income statement, its balance sheet, and the statement of cash flows.